Energenesis Biomedical to Present Clinical Application of ENERGI-F703DFU for Diabetic Foot Ulcers at EWMA 2026

Contributed by: PR Newswire

Tags

EnergenesisBiomedica

More Like This

Groundbreaking Study Reveals the Effectiveness of New RecoSMA Laser Treatment for Diabetic Foot

PR Newswire associated0

MolecuLight Featured in 11 Presentations and Posters at European Wound Management Association (EWMA) 2024 Annual Conference

PR Newswire associated0

Alphyn to Present Poster on Zabalafin Hydrogel Clinical Results at European Academy of Dermatology and Venereology Congress 2024

PR Newswire associated0

Daewoong Therapeutics Gets MFDS Nod for Phase 1 IND for the World's First Eyedrop Treatment for Diabetic Retinopathy and Macular Edema

PR Newswire associated0

MolecuLight's Innovative Approach Awarded Best Abstract at EWMA 2024

PR Newswire associated0

Pioneering Innovation from MolecuLight Earns Best Abstract at SAWC Spring 2024

Nanoform's biologics technology showcased by large pharma at drug delivery conference; Nanoenzalutamide and nanoapalutamide partnering discussions progress as planned

Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd